Harvard Bioscience Inc (HBIO) stock
HBIONasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/3040% above fair value
$9.00−0.08 (-0.88%)
Close on Nov 18, 2026Market cap $40.97MP/E –Yield –
Harvard Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Harvard Bioscience's operating income for the twelve months ending Jun 30, 2026 was -$245.00K. For fiscal 2025 it was -$48.58M. The highest annual figure on record is $10.22M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$48.58M | – |
| FY2024 | Dec 31, 2024 | -$6.21M | -427.9% |
| FY2023 | Dec 31, 2023 | $1.89M | – |
| FY2022 | Dec 31, 2022 | -$6.93M | -435.6% |
| FY2021 | Dec 31, 2021 | $2.07M | +834.8% |
| FY2020 | Dec 31, 2020 | $221.00K | -41.4% |
| FY2019 | Dec 31, 2019 | $377.00K | -61.7% |
| FY2018 | Dec 31, 2018 | $984.00K | – |
| FY2017 | Dec 31, 2017 | -$635.00K | – |
| FY2016 | Dec 31, 2016 | -$3.00M | – |
| FY2015 | Dec 31, 2015 | -$1.71M | -125.9% |
| FY2014 | Dec 31, 2014 | $6.62M | +330.6% |
| FY2013 | Dec 31, 2013 | $1.54M | -80.4% |
| FY2012 | Dec 31, 2012 | $7.83M | -6.8% |
| FY2011 | Dec 31, 2011 | $8.41M | -17.7% |
| FY2010 | Dec 31, 2010 | $10.22M | +26.9% |
| FY2009 | Dec 31, 2009 | $8.06M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$978.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.17M | – |
| Q4 FY2025 | Dec 31, 2025 | $1.71M | +15445.5% |
| Q3 FY2025 | Sep 30, 2025 | $197.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$819.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$49.67M | – |
| Q4 FY2024 | Dec 31, 2024 | $11.00K | -96.1% |
| Q3 FY2024 | Sep 30, 2024 | -$1.87M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.07M | -359.9% |
| Q1 FY2024 | Mar 31, 2024 | -$2.28M | -230.3% |
| Q4 FY2023 | Dec 31, 2023 | $282.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$933.00K | – |
| Q2 FY2023 | Jun 30, 2023 | $796.00K | -80.1% |
| Q1 FY2023 | Mar 31, 2023 | $1.75M | – |
| Q4 FY2022 | Dec 31, 2022 | -$457.00K | -126.9% |
| Q3 FY2022 | Sep 30, 2022 | -$3.76M | -786.5% |
| Q2 FY2022 | Jun 30, 2022 | $4.00M | +6793.1% |
| Q1 FY2022 | Mar 31, 2022 | -$6.71M | – |
| Q4 FY2021 | Dec 31, 2021 | $1.70M | -38.4% |
| Q3 FY2021 | Sep 30, 2021 | $548.00K | +201.1% |
| Q2 FY2021 | Jun 30, 2021 | $58.00K | -89.6% |
| Q1 FY2021 | Mar 31, 2021 | -$239.00K | – |
| Q4 FY2020 | Dec 31, 2020 | $2.76M | +68.8% |
| Q3 FY2020 | Sep 30, 2020 | $182.00K | – |
| Q2 FY2020 | Jun 30, 2020 | $556.00K | +143.9% |
| Q1 FY2020 | Mar 31, 2020 | -$3.27M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.63M | -6.3% |
| Q3 FY2019 | Sep 30, 2019 | -$1.37M | -253.4% |
| Q2 FY2019 | Jun 30, 2019 | $228.00K | – |
| Q1 FY2019 | Mar 31, 2019 | -$120.00K | – |
| Q4 FY2018 | Dec 31, 2018 | $1.74M | +365.8% |
| Q3 FY2018 | Sep 30, 2018 | $890.00K | – |
| Q2 FY2018 | Jun 30, 2018 | -$382.00K | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.27M | – |
| Q4 FY2017 | Dec 31, 2017 | $374.00K | – |
| Q3 FY2017 | Sep 30, 2017 | -$390.00K | – |
| Q2 FY2017 | Jun 30, 2017 | -$269.00K | – |
| Q1 FY2017 | Mar 31, 2017 | -$350.00K | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.12M | – |
| Q3 FY2016 | Sep 30, 2016 | -$813.00K | – |
See a number that looks wrong?